SEC Form 4 · accession 0001493152-18-010766
Insight Molecular Diagnostics Inc. · IMDX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
William Annett
Officer — President and CEO · Director
Period of report
Jul 26, 2018
Accepted (ET)
Jul 31, 2018 · 9:40 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001642380
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common stock, no par valueF1 | Jul 26, 2018 | P$0 | 3,500 | — | A | 3,500 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Common stock purchase warrantsF1 | $3.00 | Jul 26, 2018 | P | 3,500 | A | Feb 1, 2019 | Feb 1, 2024 | Common stock | 3,500 | 3,500 | D |
Explanation of responses
- F1The shares of common stock and the common stock purchase warrants reported in this Form were purchased in "units," with each unit consisting of one share of common stock and one common stock purchase warrant. The purchase price per unit was $2.86.